Please assess the completion status of the following clinical trial:

Trial Title: Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have one of the following diagnoses and/or treatment plans:~  * Newly diagnosed de novo AML~ * First or subsequent relapse of AML~ * Secondary AML~ * Treatment with institutional standard AML therapy in those without AML (for example, myelodysplastic syndrome, bone marrow blasts \> 5% or biphenotypia)~ * Note: Patients with a history of prolonged antifungal therapy (example, relapsed AML) are eligible~* Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 OR a serum creatinine based on age/gender as follows:~  * =\< 0.4 mg/dL (age 1 month to \< 6 months)~ * =\< 0.5 mg/dL (age 6 months to \< 1 year)~ * =\< 0.6 mg/dL (age 1 to \< 2 years)~ * =\< 0.8 mg/dL (age 2 to \< 6 years)~ * =\< 1 mg/dL (age 6 to \< 10 years)~ * =\< 1.2 mg/dL (age 10 to \< 13 years)~ * =\< 1.4 mg/dL (females age \>= 13 years)~ * =\< 1.5 mg/dL (males age 13 to \< 16 years)~ * =\< 1.7 mg/dL (males age \>= 16 years)~* Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age AND Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) or serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) \< 2.5 x ULN for age~* All patients and/or their parents or legal guardians must sign a written informed consent~Exclusion Criteria:~* Patients with the following diagnoses are not eligible:~  * Acute promyelocytic leukemia (APL)~ * Down syndrome~ * Juvenile myelomonocytic leukemia (JMML)~* Patients with a documented history of invasive fungal infection (IFI) within the previous 30 days are not eligible~* Patients with a history of echinocandin or fluconazole hypersensitivity are not eligible~* Patients receiving treatment for an IFI are not eligible~* Female patients of childbearing age must have a negative pregnancy test~* Patients must agree to use an effective birth control method~* Lactating patients must agree not to nurse a child while on this trial

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (caspofungin acetate) (Type: EXPERIMENTAL): Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC \> 100-500/uL following the nadir or the next chemotherapy course begins.
- Arm II (fluconazole) (Type: ACTIVE_COMPARATOR): Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course.

Based on this trial design, predict the completion outcome and termination type (if applicable).